Objective: The aim of this study was to determine whether a higher body mass index (BMI) in penile cancer patients is associated with more advanced penile cancer stage at the time of treatment and cancer survival. Methods: We evaluated 433 penile cancer patients treated between 2006 and 2012 at our institute and recorded American Joint Committee on Cancer (AJCC) stage, BMI, circumcision, smoking and age. A proportional odds model was used to assess a possible association between BMI and AJCC stage at diagnosis and controlled for circumcision, smoking and age. Five-year disease-specific survival was calculated using the Kaplan-Meier method, with the log-rank test assessing equality of distributions. Results: 433 patients with a mean BMI of 26.8 kg/m2 were analyzed. No statistically significant association between BMI and AJCC stage was found (odds ratio 1.01 per 1 kg/m2 increase in BMI, 95% confidence interval 0.97-1.05, p = 0.63). Differences in disease-specific survival were not observed based on the different BMI classes. Conclusions: No association between BMI of penile cancer patients and their disease stage at the time of treatment was observed. Thus, BMI at penile cancer treatment does not affect prognosis.

Keywords:
Body mass index, Obesity, Penile cancer, Squamous cell carcinoma
1.
Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN: Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005;116:606-616.
2.
Dillner J, von Krogh G, Horenblas S, Meijer CJ: Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000;205:189-193.
3.
Basen-Engquist K, Chang M: Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011;13:71-76.
4.
Barnes KT, Smith BJ, Lynch CF, Gupta A: Obesity and invasive penile cancer. Eur Urol 2013;63:588-589.
5.
Kampman E, Vrieling A, van Duijnhoven FJ, Winkels RM: Impact of diet, body mass index, and physical activity on cancer survival. Curr Nutr Rep 2012;1:30-36.
6.
Djajadiningrat RS, Graafland NM, van Werkhoven E, Meinhardt W, Bex A, van der Poel HG, van Boven HH, Valdés Olmos RA, Horenblas S: Contemporary management of regional nodes in penile cancer: improvement of survival? J Urol 2014;191:68-73.
7.
Edge S, Byrd D, Compton C: AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
8.
Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumours, ed 7. Oxford, Wiley-Blackwell, 2010.
9.
Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM, Horenblas S, Aaronson NK: Quality of life for patients treated for penile cancer. J Urol 2014;192:1105-1110.
10.
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index): National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-567.
11.
Abdulla A, Daya D, Pinthus J, Davies T: Buried penis: an unrecognized risk factor in the development of invasive penile cancer. Can Urol Assoc J 2012;6:199-201.
12.
Hofer MD, Meeks JJ, Mehdiratta N, Granieri MA, Cashy J, Gonzalez CM: Lichen sclerosus in men is associated with elevated body mass index, diabetes mellitus, coronary artery disease and smoking. World J Urol 2014;32:105-108.
13.
Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ: Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009;27:141-150.
14.
Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR: Incidence trends in primary malignant penile cancer. Urol Oncol 2007;25:361-367.
15.
Ewertz M, Jensen MB, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S: Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25-31.
16.
Vrieling A, Kampman E: The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr 2010;92:471-491.
17.
Cao Y, Ma J: Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 2011;4:486-501.
18.
Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, Cai XL, Xie X, Liu QW, Bella AE, Hu RG, Wen J, Hu Y, Fu JH: The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer 2013;109:2894-2903.
19.
Pai PC, Chuang CC, Tseng CK, Tsang NM, Chang KP, Yen TC, Liao CT, Hong JH, Chang JT: Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 2012;83:e93-e100.
20.
Gaudet MM, Patel AV, Sun J, Hildebrand JS, McCullough ML, Chen AY, Gapstur SM: Prospective studies of body mass index with head and neck cancer incidence and mortality. Cancer Epidemiol Biomarkers Prev 2012;21:497-503.
21.
Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, Snijders PJ: Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006;119:1078-1081.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.